Related Experiment Videos
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma
K Bertelsen1, A Jakobsen, J E Andersen
1Danish Ovarian Cancer Group, Department of Oncology, University Hospital, Odense, Denmark.
Gynecologic Oncology
|October 1, 1987
Abstract:
Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.